True Wealth Design
AGIO icon

True Wealth Design’s Agios Pharmaceuticals AGIO Stock Holding History

True Wealth Design’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.4K Buy
314
+8
+3% +$280 ﹤0.01% 1046
2026
Q2 		$11.4K Buy
306
+294
+2,450% +$8.92K ﹤0.01% 1023
2026
Q1 		$406 Buy
+12
New +$340 ﹤0.01% 2121
2025
Q4 		– Sell
-9
Closed -$362 – 2562
2025
Q3 		$362 Hold
9
– – ﹤0.01% 2111
2025
Q2 		$300 Buy
9
+4
+80% +$121 ﹤0.01% 1934
2025
Q1 		$147 Buy
+5
New +$166 ﹤0.01% 2069
2024
Q4 		– Sell
-166
Closed -$7.38K – 1354
2024
Q3 		$7.38K Buy
+166
New +$7.54K ﹤0.01% 478

Other funds holding AGIO

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

True Wealth Design's AGIO Position: Q3 2026 in Review

True Wealth Design increased its Agios Pharmaceuticals (AGIO) stake by 2.6% in Q3 2026, buying an estimated $280 and bringing the position to 314 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1046.

True Wealth Design first reported a position in AGIO in Q3 2024 and has held it in 7 quarters since. The position peaked at $11.4K in Q2 2026. 20 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

  • True Wealth Design held 314 shares of Agios Pharmaceuticals worth $10.4K as of Q3 2026.
  • True Wealth Design bought 8 Agios Pharmaceuticals shares in Q3 2026, an estimated $280.
  • Agios Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #1046 holding.
  • True Wealth Design first reported a position in Agios Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • True Wealth Design's Agios Pharmaceuticals position peaked at $11.4K in Q2 2026.
  • 20 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.